Eli Lilly Announces Detailed Results From TRIUMPH-2; TRIUMPH-2 Participants With Obesity And Type 2 Diabetes Taking Retatrutide 12 Mg Lost An Average Of 49.6 Lbs Over 80 Weeks; Retatrutide 12 Mg Leads To 60.8 Lb Weight Loss In BMI ≥35 Group; To Submit Biologics License Application For Retatrutide In Q1 2027
In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half no longer meeting the BMI criteria for obesityParticipants with
Eli Lilly's new weight loss drug showed strong results in testing. When people used it for 80 weeks, they lost almost 50 pounds on average.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.